Engineered adipose-derived stem cells with self-amplifying RNA enhance vascular network formation in porous GelMA hydrogels.
Vanlauwe F., De Witte T., Michiels G., Eeckhout V., Dewaele A., De Meulenaere A.
Laboratory Study, published in Biomater Sci (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Biomater Sci (2026)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42599124
- DOI
- 10.1039/d6bm00076b
Abstract (original English)
Dependence on exogenous growth factor (GF) supplementation of culture media and the limited diffusion of these GFs in densely populated hydrogel structures remain major obstacles to achieving extensive vascularization in engineered tissues. Here, we introduce a biofabrication strategy that embeds cellulose-purified self-amplifying RNA (saRNA)-engineered adipose-derived stem cells (ASCs) within hydrogels constructs, enhancing endogenous GF production and paracrine signaling. Compared with a no-transfection control, which exhibited only 10 ± 7 mm mm -3 of vasculogenic network formation and 0.2 ± 0.25 mm of sprouting per spheroid within porous gelatin methacryloyl scaffolds, dual VEGF/FGF2 expression induced by saRNA produced markedly stronger outcomes, yielding 25.3 ± 11.3 mm mm -3 of network formation and 1.85 ± 0.8 mm of sprouting after 7 days of culture. This system is also compatible with 3D bioprinting, enabling engineered ASCs to be precisely bioprinted at defined locations within the hydrogel structure. Moreover, within bioprinted constructs, this system allows microvascular networks formed by engineered spheroids to extend toward surrounding macrovascular channel structures. Collectively, these results demonstrate a versatile platform where cell-mediated GF delivery promotes vascularization of tissue-engineered constructs while substantially minimizing the need for exogen
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.